Literature DB >> 24276560

Progesterone and estrogen receptors in conjunctival melanoma and nevi.

Laura Bredow1, Lisa Stützel, Daniel Böhringer, Enken Gundlach, Thomas Reinhard, Claudia Auw-Haedrich.   

Abstract

BACKGROUND: Since it has been observed that melanocytic lesions can alter their appearance during pregnancy, we analyzed whether hormone receptors are expressed in conjunctival nevi as well as conjunctival melanoma. We further analyzed whether the number of estrogen (ER) or progesterone receptors (PR) might be associated with the disease course in conjunctival melanoma.
METHODS: Twenty-seven paraffin-embedded samples of conjunctival nevi and 27 conjunctival melanoma specimens were examined using immunohistological analysis with antibodies against PR and ER. The percentage of stained cells were analyzed, taking into account patient gender and age. Out of the melanoma group, all patients with complete data for tumor thickness, tumor localization, age at diagnosis, gender, and follow-up including recurrence, metastasis and tumor-related death were included in the second part of the study (n = 15), where hormone receptor rates were associated with tumor outcome, regarding recurrences, metastasis or death. Written consent was received from all included patients.
RESULTS: Both nevi and melanomas showed high rates of PR- and ER-positive cells. In Nevi, 64 ± 25 % of cells stained positive for PR and 35 ± 34 % for ER. In melanoma specimens, 68 ± 30 % showed PR and 44 ± 34 % ER expression. Differences between men and women in expression rates were not statistically significant. Out of 15 melanoma patients (nine female, six male), 53 % (five women and three men) experienced 1-4 recurrences, and four patients developed metastases. The median estimated survival time was 12.2 years. A multivariate survival model taking into account known risk factors for prognosis in conjunctival melanoma confirmed tumor location to be an important predictive factor for outcome (p = 0.05). The rate of PR or ER did not show a statistically significant correlation with the disease course in our cohort.
CONCLUSIONS: We observed that conjunctival melanocytic lesions express hormone receptors, which could explain why these tumors can alter their appearance under hormonal changes. Regarding the prognosis of conjunctival melanoma, no statistically significant correlation between hormone receptor expression and event-free survival was found in this analysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24276560     DOI: 10.1007/s00417-013-2523-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  24 in total

1.  Identification of androgen, estrogen and progesterone receptor mRNAs in the eye.

Authors:  L A Wickham; J Gao; I Toda; E M Rocha; M Ono; D A Sullivan
Journal:  Acta Ophthalmol Scand       Date:  2000-04

Review 2.  Conjunctival melanoma: pitfalls and dilemmas in management.

Authors:  Yevgeniy Shildkrot; Matthew W Wilson
Journal:  Curr Opin Ophthalmol       Date:  2010-09       Impact factor: 3.761

3.  Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites.

Authors:  Seppo Tuomaala; Sebastian Eskelin; Ahti Tarkkanen; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-11       Impact factor: 4.799

4.  Immunohistochemical evidence for estrogen receptors in meibomian glands.

Authors:  B Esmaeli; J T Harvey; B Hewlett
Journal:  Ophthalmology       Date:  2000-01       Impact factor: 12.079

5.  Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study.

Authors:  Gerasimos Anastassiou; Arnd Heiligenhaus; Nikos Bechrakis; Elisabeth Bader; Norbert Bornfeld; Klaus-Peter Steuhl
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

6.  Long-term follow-up of patients with conjunctival melanoma.

Authors:  Cornelia Werschnik; Peter K Lommatzsch
Journal:  Am J Clin Oncol       Date:  2002-06       Impact factor: 2.339

Review 7.  Nevi and melanoma in pregnancy.

Authors:  Marcia S Driscoll; Jane M Grant-Kels
Journal:  Dermatol Clin       Date:  2006-04       Impact factor: 3.478

8.  Conjunctival melanoma in the Netherlands: a nationwide study.

Authors:  Guy S Missotten; Sander Keijser; Rob J W De Keizer; Didi De Wolff-Rouendaal
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

9.  Conjunctival melanoma: is it increasing in the United States?

Authors:  Guo-Pei Yu; Dan-Nin Hu; Steven McCormick; Paul T Finger
Journal:  Am J Ophthalmol       Date:  2003-06       Impact factor: 5.258

10.  An audit of conjunctival melanoma treatment in Liverpool.

Authors:  B Damato; S E Coupland
Journal:  Eye (Lond)       Date:  2008-06-06       Impact factor: 3.775

View more
  3 in total

1.  Conjunctival Melanoma during Pregnancy.

Authors:  Rana'a T Al-Jamal; Hardeep Singh Mudhar; Zanna Currie; Ian G Rennie; Sachin M Salvi
Journal:  Ocul Oncol Pathol       Date:  2016-11-08

Review 2.  Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.

Authors:  Tamás Deli; Mónika Orosz; Attila Jakab
Journal:  Pathol Oncol Res       Date:  2019-01-08       Impact factor: 3.201

3.  Transcriptional characterization of conjunctival melanoma identifies the cellular tumor microenvironment and prognostic gene signatures.

Authors:  Julian Wolf; Claudia Auw-Haedrich; Anja Schlecht; Stefaniya Boneva; Hans Mittelviefhaus; Thabo Lapp; Hansjürgen Agostini; Thomas Reinhard; Günther Schlunck; Clemens A K Lange
Journal:  Sci Rep       Date:  2020-10-12       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.